Top

Published in:

01-02-2018 | Original Paper

Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease

Authors: Isabelle St-Amour, Andréanne Turgeon, Claudia Goupil, Emmanuel Planel, Sébastien S. Hébert

Published in: Acta Neuropathologica | Issue 2/2018

Abstract

Accumulating evidence highlights the potential role of mixed proteinopathies (i.e., abnormal protein aggregation) in the development of clinical manifestations of neurodegenerative diseases (NDD). Huntington’s disease (HD) is an inherited NDD caused by autosomal-dominant expanded CAG trinucleotide repeat mutation in the gene coding for Huntingtin (Htt). Previous studies have suggested the coexistence of phosphorylated-Tau, α-synuclein (α-Syn) and TAR DNA-binding protein 43 (TDP-43) inclusions in HD. However, definite evidence that HD pathology in humans can be accompanied by other proteinopathies is still lacking. Using human post-mortem putamen samples from 31 controls and 56 HD individuals, we performed biochemical analyses of the expression, oligomerization and aggregation of Tau, α-Syn, TDP-43, and Amyloid precursor protein (APP)/Aβ. In HD brain, we observed reduced soluble protein (but not mRNA) levels of Htt, α-Syn, and Tau. Our results also support abnormal phosphorylation of Tau in more advanced stages of disease. Aberrant splicing of Tau exons 2, 3 (exclusion) and 10 (inclusion) was also detected in HD patients, leading to higher 0N4R and lower 1N3R isoforms. Finally, following formic acid extraction, we observed increased aggregation of TDP-43, α-Syn, and phosphorylated-Tau during HD progression. Notably, we observed that 88% of HD patients with Vonsattel grade 4 neuropathology displayed at least one non-Htt proteinopathy compared to 29% in controls. Interestingly, α-Syn aggregation correlated with Htt, TDP-43 and phosphorylated-Tau in HD but not in controls. The impact of this work is twofold: (1) it provides compelling evidences that Tau, α-Syn and TDP-43 proteinopathies are increased in HD, and (2) it suggests the involvement of common mechanisms leading to abnormal accumulation of aggregation-prone proteins in NDD. Further studies will be needed to decipher the impact of these proteinopathies on clinical manifestation of HD.

Available only for authorised users

Arai T, Mackenzie IR, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136. https://doi.org/10.1007/s00401-008-0480-1 CrossRefPubMed

Aronin N, Chase K, Young C et al (1995) CAG expansion affects the expression of mutant Huntingtin in the Huntington’s disease brain. Neuron 15:1193–1201CrossRefPubMed

Blum D, Herrera F, Francelle L et al (2015) Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Genet 24:76–85. https://doi.org/10.1093/hmg/ddu421 CrossRefPubMed

Braisch U, Hay B, Muche R et al (2017) Identification of extreme motor phenotypes in Huntington’s disease. Am J Med Genet B Neuropsychiatr Genet 174:283–294. https://doi.org/10.1002/ajmg.b.32514 CrossRefPubMed

Buée L, Bussière T, Buée-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130CrossRefPubMed

Caillet-Boudin ML, Buée L, Sergeant N, Lefebvre B (2015) Regulation of human MAPT gene expression. Mol Neurodegener 10:28. https://doi.org/10.1186/s13024-015-0025-8 CrossRefPubMedPubMedCentral

Charles V, Mezey E, Reddy PH et al (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett 289:29–32CrossRefPubMed

Conrad C, Zhu J, Conrad C et al (2007) Single molecule profiling of tau gene expression in Alzheimer’s disease. J Neurochem 103:1228–1236. https://doi.org/10.1111/j.1471-4159.2007.04857.x CrossRefPubMed

Corrochano S, Renna M, Carter S et al (2012) α-Synuclein levels modulate Huntington’s disease in mice. Hum Mol Genet 21:485–494. https://doi.org/10.1093/hmg/ddr477 CrossRefPubMed

10.

Cubillos-Rojas M, Amair-Pinedo F, Tato I et al (2010) Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using Tris-acetate polyacrylamide gels. Electrophoresis 31:1318–1321. https://doi.org/10.1002/elps.200900657 CrossRefPubMed

11.

Davis MY, Keene CD, Jayadev S et al (2014) The co-occurrence of Alzheimer’s disease and Huntington’s disease: a neuropathological study of 15 elderly Huntington’s disease subjects. J Huntingtons Dis 3:209–217. https://doi.org/10.3233/JHD-140111 PubMed

12.

DiFiglia M, Sapp E, Chase KO et al (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993CrossRefPubMed

13.

Edmonds EC, Bangen KJ, Delano-Wood L et al (2016) Patterns of cortical and subcortical amyloid burden across stages of preclinical Alzheimer’s disease. J Int Neuropsychol Soc 22:978–990. https://doi.org/10.1017/S1355617716000928 CrossRefPubMedPubMedCentral

14.

Elobeid A, Libard S, Leino M et al (2016) Altered proteins in the aging brain. J Neuropathol Exp Neurol 75:316–325. https://doi.org/10.1093/jnen/nlw002 CrossRefPubMedPubMedCentral

15.

Fernandez-Nogales M, Cabrera JR, Santos-Galindo M et al (2014) Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881–885. https://doi.org/10.1038/nm.3617 CrossRefPubMed

16.

Fourie C, Kim E, Waldvogel H et al (2014) Differential changes in postsynaptic density proteins in postmortem Huntington’s disease and Parkinson’s disease human brains. J Neurodegener Dis 2014:938530. https://doi.org/10.1155/2014/938530 PubMedPubMedCentral

17.

Golde TE, Borchelt DR, Giasson BI et al (2013) Thinking laterally about neurodegenerative proteinopathies. J Clin Invest 123:1847–1855. https://doi.org/10.1172/JCI66029 CrossRefPubMedPubMedCentral

18.

Gratuze M, Cisbani G, Cicchetti F et al (2016) Is Huntington’s disease a tauopathy. Brain 139:1014–1025. https://doi.org/10.1093/brain/aww021 CrossRefPubMed

19.

Gratuze M, Noël A, Julien C et al (2015) Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington’s disease. Hum Mol Genet 24:86–99. https://doi.org/10.1093/hmg/ddu456 CrossRefPubMed

20.

Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 87:5827–5831CrossRefPubMedPubMedCentral

21.

Hensman Moss DJ, Flower MD, Lo KK et al (2017) Huntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s disease. Sci Rep 7:44849. https://doi.org/10.1038/srep44849 CrossRefPubMedPubMedCentral

22.

Hernandez-Rapp J, Rainone S, Goupil C et al (2016) microRNA-132/212 deficiency enhances Aβ production and senile plaque deposition in Alzheimer’s disease triple transgenic mice. Sci Rep 6:30953. https://doi.org/10.1038/srep30953 CrossRefPubMedPubMedCentral

23.

Hodges A, Strand AD, Aragaki AK et al (2006) Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet 15:965–977. https://doi.org/10.1093/hmg/ddl013 CrossRefPubMed

24.

Hoffner G, Djian P (2014) Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain Sci 4:91–122. https://doi.org/10.3390/brainsci4010091 CrossRefPubMedPubMedCentral

25.

Hoffner G, Island ML, Djian P (2005) Purification of neuronal inclusions of patients with Huntington’s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem 95:125–136. https://doi.org/10.1111/j.1471-4159.2005.03348.x CrossRefPubMed

26.

Hosokawa M, Kondo H, Serrano GE et al (2017) Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. Sci Rep 7:1513. https://doi.org/10.1038/s41598-017-01587-6 CrossRefPubMedPubMedCentral

27.

Jacobs M, Hart EP, van Zwet EW et al (2016) Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study. J Neurol 263:2080–2085. https://doi.org/10.1007/s00415-016-8233-x CrossRefPubMedPubMedCentral

28.

Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm (Vienna) 105:787–799. https://doi.org/10.1007/s007020050095 CrossRef

29.

Jellinger KA, Attems J (2015) Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) 122:505–521. https://doi.org/10.1007/s00702-014-1288-x CrossRef

30.

Josephs KA, Whitwell JL, Tosakulwong N et al (2015) TAR DNA-binding protein 43 and pathological subtype of Alzheimer’s disease impact clinical features. Ann Neurol 78:697–709. https://doi.org/10.1002/ana.24493 CrossRefPubMedPubMedCentral

31.

Julien C, Bretteville A, Planel E (2012) Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies. Methods Mol Biol 849:473–491. https://doi.org/10.1007/978-1-61779-551-0_32 CrossRefPubMed

32.

Kametani F, Obi T, Shishido T et al (2016) Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep 6:23281. https://doi.org/10.1038/srep23281 CrossRefPubMedPubMedCentral

33.

Kanai K, Kuwabara S, Sawai S et al (2008) Genetically confirmed Huntington’s disease masquerading as motor neuron disease. Mov Disord 23:748–751. https://doi.org/10.1002/mds.21937 CrossRefPubMed

34.

Kloppel S, Gregory S, Scheller E et al (2015) Compensation in preclinical Huntington’s disease: evidence from the track-on HD study. EBioMedicine 2:1420–1429. https://doi.org/10.1016/j.ebiom.2015.08.002 CrossRefPubMedPubMedCentral

35.

Kovacs GG, Murrell JR, Horvath S et al (2009) TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 24:1843–1847. https://doi.org/10.1002/mds.22697 CrossRefPubMed

36.

L’Episcopo F, Drouin-Ouellet J, Tirolo C et al (2016) GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington’s disease: involvement of astrocyte–neuron interactions. Cell Death Dis 7:e2206. https://doi.org/10.1038/cddis.2016.104 CrossRefPubMedPubMedCentral

37.

Labadorf A, Hoss AG, Lagomarsino V et al (2015) RNA sequence analysis of human huntington disease brain reveals an extensive increase in inflammatory and developmental gene expression. PLoS One 10:e0143563. https://doi.org/10.1371/journal.pone.0143563 CrossRefPubMedPubMedCentral

38.

Landwehrmeyer GB, McNeil SM, Dure LS et al (1995) Huntington’s disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol 37:218–230. https://doi.org/10.1002/ana.410370213 CrossRefPubMed

39.

Larson ME, Sherman MA, Greimel S et al (2012) Soluble α-synuclein is a novel modulator of Alzheimer’s disease pathophysiology. J Neurosci 32:10253–10266. https://doi.org/10.1523/JNEUROSCI.0581-12.2012 CrossRefPubMedPubMedCentral

40.

Lautenschlager J, Kaminski CF, Kaminski Schierle GS (2017) α-Synuclein—regulator of exocytosis, endocytosis, or both. Trends Cell Biol 27:468–479. https://doi.org/10.1016/j.tcb.2017.02.002 CrossRefPubMed

41.

Liu C, Götz J (2013) Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLoS One 8:e84849. https://doi.org/10.1371/journal.pone.0084849 CrossRefPubMedPubMedCentral

42.

Mason SL, Zhang J, Begeti F et al (2015) The role of the amygdala during emotional processing in Huntington’s disease: from pre-manifest to late stage disease. Neuropsychologia 70:80–89. https://doi.org/10.1016/j.neuropsychologia.2015.02.017 CrossRefPubMedPubMedCentral

43.

Masuda-Suzukake M, Nonaka T, Hosokawa M et al (2014) Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2:88. https://doi.org/10.1186/PREACCEPT-1296467154135944 CrossRefPubMedPubMedCentral

44.

Mehrabi NF, Waldvogel HJ, Tippett LJ et al (2016) Symptom heterogeneity in Huntington’s disease correlates with neuronal degeneration in the cerebral cortex. Neurobiol Dis 96:67–74. https://doi.org/10.1016/j.nbd.2016.08.015 CrossRefPubMed

45.

Miller JR, Lo KK, Andre R et al (2016) RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet 25:2893–2904. https://doi.org/10.1093/hmg/ddw142 CrossRefPubMedPubMedCentral

46.

Nakabayashi J, Yoshimura M, Morishima-Kawashima M et al (1998) Amyloid beta-protein (A beta) accumulation in the putamen and mammillary body during aging and in Alzheimer disease. J Neuropathol Exp Neurol 57:343–352CrossRefPubMed

47.

Niblock M, Gallo JM (2012) Tau alternative splicing in familial and sporadic tauopathies. Biochem Soc Trans 40:677–680. https://doi.org/10.1042/BST20120091 CrossRefPubMed

48.

Orth M, Handley OJ, Schwenke C et al (2010) Observing Huntington’s disease: the European Huntington’s disease network’s REGISTRY. PLoS Curr 2:184. https://doi.org/10.1371/currents.RRN1184

49.

Papageorgiou SG, Antelli A, Bonakis A et al (2006) Association of genetically proven Huntington’s disease and sporadic amyotrophic lateral sclerosis in a 72-year-old woman. J Neurol 253:1649–1650. https://doi.org/10.1007/s00415-006-0267-z CrossRefPubMed

50.

Papoutsi M, Labuschagne I, Tabrizi SJ et al (2014) The cognitive burden in Huntington’s disease: pathology, phenotype, and mechanisms of compensation. Mov Disord 29:673–683. https://doi.org/10.1002/mds.25864 CrossRefPubMed

51.

Park SA, Ahn SI, Gallo JM (2016) Tau mis-splicing in the pathogenesis of neurodegenerative disorders. BMB Rep 49:405–413CrossRefPubMedPubMedCentral

52.

Penney JB, Vonsattel JP, MacDonald ME et al (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41:689–692. https://doi.org/10.1002/ana.410410521 CrossRefPubMed

53.

Petry FR, Pelletier J, Bretteville A et al (2014) Specificity of anti-tau antibodies when analyzing mice models of Alzheimer’s disease: problems and solutions. PLoS One 9:e94251. https://doi.org/10.1371/journal.pone.0094251 CrossRefPubMedPubMedCentral

54.

Poças GM, Branco-Santos J, Herrera F et al (2015) α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila. Hum Mol Genet 24:1898–1907. https://doi.org/10.1093/hmg/ddu606 CrossRefPubMed

55.

Rosa FE, Silveira SM, Silveira CG et al (2009) Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 9:90. https://doi.org/10.1186/1471-2407-9-90 CrossRefPubMedPubMedCentral

56.

Rosas HD, Salat DH, Lee SY et al (2008) Complexity and heterogeneity: what drives the ever-changing brain in Huntington’s disease. Ann N Y Acad Sci 1147:196–205. https://doi.org/10.1196/annals.1427.034 CrossRefPubMedPubMedCentral

57.

Rosenblatt A, Kumar BV, Mo A et al (2012) Age, CAG repeat length, and clinical progression in Huntington’s disease. Mov Disord 27:272–276. https://doi.org/10.1002/mds.24024 CrossRefPubMed

58.

Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83–98. https://doi.org/10.1016/S1474-4422(10)70245-3 CrossRefPubMed

59.

Rüb U, Seidel K, Heinsen H et al (2016) Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol 26:726–740. https://doi.org/10.1111/bpa.12426 CrossRefPubMed

60.

Sadeghian H, O’Suilleabhain PE, Battiste J et al (2011) Huntington chorea presenting with motor neuron disease. Arch Neurol 68:650–652. https://doi.org/10.1001/archneurol.2011.76 CrossRefPubMed

61.

Schilling G, Sharp AH, Loev SJ et al (1995) Expression of the Huntington’s disease (IT15) protein product in HD patients. Hum Mol Genet 4:1365–1371CrossRefPubMed

62.

Schwab C, Arai T, Hasegawa M et al (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67:1159–1165. https://doi.org/10.1097/NEN.0b013e31818e8951 CrossRefPubMed

63.

Sieradzan KA, Mechan AO, Jones L et al (1999) Huntington’s disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156:92–99. https://doi.org/10.1006/exnr.1998.7005 CrossRefPubMed

64.

Smith R, Klein P, Koc-Schmitz Y et al (2007) Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington’s disease. J Neurochem 103:115–123. https://doi.org/10.1111/j.1471-4159.2007.04703.x PubMed

65.

Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134:187–205. https://doi.org/10.1007/s00401-017-1709-7 CrossRefPubMedPubMedCentral

66.

Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801. https://doi.org/10.1016/S1474-4422(09)70170-X CrossRefPubMedPubMedCentral

67.

Tada M, Coon EA, Osmand AP et al (2012) Coexistence of Huntington’s disease and amyotrophic lateral sclerosis: a clinicopathologic study. Acta Neuropathol 124:749–760. https://doi.org/10.1007/s00401-012-1005-5 CrossRefPubMedPubMedCentral

68.

Takeuchi R, Tada M, Shiga A et al (2016) Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: evidence for clinico-pathologic subtypes. Acta Neuropathol Commun 4:61. https://doi.org/10.1186/s40478-016-0335-2 CrossRefPubMedPubMedCentral

69.

The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRef

70.

Tomas-Zapico C, Díez-Zaera M, Ferrer I et al (2012) α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington’s disease. Hum Mol Genet 21:495–510. https://doi.org/10.1093/hmg/ddr507 CrossRefPubMed

71.

Tremblay C, François A, Delay C et al (2017) Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. https://doi.org/10.1093/jnen/nlw109 PubMed

72.

Tremblay C, St-Amour I, Schneider J et al (2011) Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 70:788–798. https://doi.org/10.1097/NEN.0b013e31822c62cf CrossRefPubMedPubMedCentral

73.

Tse C, Brault D, Gligorov J et al (2005) Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin Chem 51:1093–1101. https://doi.org/10.1373/clinchem.2004.044305 CrossRefPubMed

74.

Uchino A, Takao M, Hatsuta H et al (2015) Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun 3:35. https://doi.org/10.1186/s40478-015-0215-1 CrossRefPubMedPubMedCentral

75.

Vuono R, Winder-Rhodes S, de Silva R et al (2015) The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138:1907–1918. https://doi.org/10.1093/brain/awv107 CrossRefPubMedPubMedCentral

76.

Waldvogel HJ, Thu D, Hogg V et al (2012) Selective neurodegeneration, neuropathology and symptom profiles in Huntington’s disease. Adv Exp Med Biol 769:141–152CrossRefPubMed

77.

Xuereb JH, MacMillan JC, Snell R et al (1996) Neuropathological diagnosis and CAG repeat expansion in Huntington’s disease. J Neurol Neurosurg Psychiatry 60:78–81CrossRefPubMedPubMedCentral

78.

Yin X, Jin N, Gu J et al (2012) Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. J Biol Chem 287:30497–30506. https://doi.org/10.1074/jbc.M112.355412 CrossRefPubMedPubMedCentral

Title: Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease
Authors: Isabelle St-Amour
Andréanne Turgeon
Claudia Goupil
Emmanuel Planel
Sébastien S. Hébert
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 2/2018
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-017-1786-7

At a glance: The STEP trials

Springer Medicine

Co-occurrence of mixed proteinopathies in late-stage Huntington’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness

Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis

Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology

The function of the cellular prion protein in health and disease

Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis